(Q62818096)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

title

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

ChEBI release 2020-05-28

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

author name string

A Pardanani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

J Gotlib

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

M Wadleigh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

S Sirhan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

J Kawashima

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

J A Maltzman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

L Shao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

V Gupta

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

A Tefferi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

publication date

16 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

7 April 2020

page(s)

1035-1038

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29263442%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2017.330

7 April 2020

exact match

0 references

cites work

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

What are RBC-transfusion-dependence and -independence?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.330

7 January 2021

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29263442

12 December 2020